The main treatment for glaucoma is currently topical drugs to control IOP and protect vision. The drug discovery and development process are evolving in order to better treat glaucoma. To understand the effects of anti-glaucoma drugs, it is important to pharmacodynamically study the action of the drug or drug candidate in the in vivo environment.
With years of experience in pharmacodynamic research and outstanding expertise, Ace Therapeutics offers you pharmacodynamic evaluation services in animal models of glaucoma, using advanced ophthalmic techniques to explore the efficacy of specific drugs.
The Importance of Pharmacodynamics Study for Glaucoma Drugs
Because the eye has unique anatomical and physiological limitations, treatments for glaucoma are generally optimized by targeted drug delivery to specific ocular tissues. Therefore, achieving and maintaining efficacy in specific ocular sites for different drug delivery systems and therapeutic targets requires a clear understanding of the pathophysiology of glaucoma as well as the pharmacokinetics and pharmacodynamics of the drug. Pharmacodynamics generally involves the study of the mechanisms of drug action at the molecular, cellular and tissue levels.
Pharmacodynamics is the study of the physiological and biochemical effects of drugs and the discovery of mechanisms of action. Pharmacodynamics emphasizes the relationship between drug concentrations and their effects, and can predict adverse reactions to drugs in humans. We often establish animal models of glaucoma to provide opportunities for pharmacodynamic studies. Animal models simulate the condition of human glaucoma, in which we are able to quantitatively predict the effects of drugs on the eye. Animal models in pharmacodynamic evaluation play an important role in the preclinical evaluation of new drugs.
Services for Pharmacodynamics Study for Glaucoma Drugs
Our global team of industry-leading scientists uses a variety of state-of-the-art ophthalmic techniques and imaging modalities to study the pharmacodynamics of novel compounds targeting the treatment of glaucoma. We offer a wide range of ocular models for glaucoma and are interested in collaborative model development on new and unique models. This combined with preclinical research experience allows us to support our clients' glaucoma program research needs.
- Supported animal model species. We offer in vivo pharmacology studies in nearly dozens of animal models to simulate the condition of the human eye. Species covered include, but are not limited to, mice, rats, rabbits, non-human primates, etc.
- Comprehensive dosing technology. We offer intravitreal, subretinal, subconjunctival, anterior chamber, and systemic dosing techniques for different species types and routes of administration.
- Available assessment items. You can choose or customize the examinations you need. We offer specific services including, but not limited to, anterior segment testing, fundus testing, optical coherence tomography (OCT), electroretinography (ERG), intraocular pressure (IOP) measurement, gene expression, etc.
- Professional ophthalmic equipment. Our team uses a variety of state-of-the-art technologies and equipment for animal eye research, including, Kowa handheld slit lamp, Topcon slit lamp, Leica surgical scope, Heidelberg Spectralis OCT, Volk PictorPlus, etc.
Pharmacodynamic Modeling
Our innovative services include the construction of ocular pharmacodynamic models for glaucoma drugs, capable of reliably predicting IOP in the context of polypharmacy or new drug therapy. Based primarily on theoretical foundations of pharmacokinetics, pharmacodynamics, and toxicology, such models can predict drug response and thus optimize ocular drug therapy.
For questions about your glaucoma program or if you need help, contact us to get expert help.
References
- Sakanaka K, et al. Ocular pharmacokinetic/pharmacodynamic modeling for multiple anti-glaucoma drugs. Biol Pharm Bull, 2008, 31(8):1590-5.
- Sharif N A. Pharmacodynamic Evaluation: Ocular Pharmacology. Drug Discovery and Evaluation: Methods in Clinical Pharmacology, 2020: 163-208.